Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
AbbVie remains a Buy despite venetoclax's MDS trial failure, as this setback has minimal impact on current revenue and growth outlook. SKYRIZI and RINVOQ are successfully replacing HUMIRA's lost revenue, driving robust year-over-year growth and demonstrating AbbVie's R&D strength. AbbVie's diversified pipeline, strategic partnerships, and expansion into oncology and neuroscience provide multiple growth drivers beyond immunology.
![]() ABBV In 4 weeks Estimated | Quarterly | $1.64 Per Share |
![]() ABBV 2 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 5 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 8 months ago Paid | Quarterly | $1.55 Per Share |
![]() ABBV 11 months ago Paid | Quarterly | $1.55 Per Share |
![]() ABBV 12 Apr 2024 Paid | Quarterly | $1.55 Per Share |
23 Jul 2025 (36 Days) Date | | - Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | 2.26 Cons. EPS | 2.16 EPS |
30 Oct 2024 Date | | 2.92 Cons. EPS | 3 EPS |
25 Oct 2024 Date | | 2.95 Cons. EPS | - EPS |
![]() ABBV In 4 weeks Estimated | Quarterly | $1.64 Per Share |
![]() ABBV 2 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 5 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 8 months ago Paid | Quarterly | $1.55 Per Share |
![]() ABBV 11 months ago Paid | Quarterly | $1.55 Per Share |
![]() ABBV 12 Apr 2024 Paid | Quarterly | $1.55 Per Share |
23 Jul 2025 (36 Days) Date | | - Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | 2.26 Cons. EPS | 2.16 EPS |
30 Oct 2024 Date | | 2.92 Cons. EPS | 3 EPS |
25 Oct 2024 Date | | 2.95 Cons. EPS | - EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Mr. Robert A. Michael CPA CEO | XMIL Exchange | US00287Y1091 ISIN |
US Country | 55,000 Employees | 15 Apr 2025 Last Dividend | - Last Split | 2 Jan 2013 IPO Date |
AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.